Skip to main content
SpringerLink
Log in

Clinical Pharmacokinetics of Topotecan

  • Review Article
  • Drug Disposition
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Summary

Topotecan (Hycamtin®), a semisynthetic water-soluble derivative of camptothecin, is a potent inhibitor of DNA topoisomerase I in vitro and has demonstrated encouraging antitumour activity in a wide variety of tumours, including ovarian cancer and small cell lung cancer. Now approved in the US, topotecan has completed single-agent phase I testing; phase II/III trials are ongoing.

Under physiological conditions the lactone moiety of topotecan undergoes a rapid and reversible pH-dependent conversion to a carboxylated open-ring form, which lacks topoisomerase I inhibiting activity. At equilibrium at pH 7.4 the open-ring form predominates. Topotecan is stable in infusion fluids in the presence of tartaric acid (pH < 4.0), but is unstable in plasma, requiring immediate deproteinisation with cold methanol after blood sampling and storage of the extract at −30°C to preserve the lactone form.

Topotecan has been administered in phase I trials in several infusion schedules ranging from 30 minutes to 21 days. The plasma decay of topotecan concentrations usually fits a 2-compartment model. Rapid hydrolysis of topotecan lactone results in plasma carboxylate levels exceeding lactone levels as early as 45 minutes after the start of a 30-minute infusion. The peak plasma concentrations and the area under the plasma concentration-versus-time curves (AUC) show linear relationship with increasing dosages. No evidence of drug accumulation is seen with daily 30-minute infusions for 5 consecutive days.

Topotecan lactone is widely distributed into the peripheral space, with a mean volume of distribution (Vd) at steady-state of 75 L/m2. The mean total body clearance of the lactone form is 30 L/h/m2, with a mean elimination half-life (t½β) of 3 hours; renal clearance accounts for approximately 40% of the administered dose with a large interindividual variability.

The oral bioavailability of topotecan is approximately 35%. The low bioavailability may be caused by hydrolysis of topotecan lactone in the gut, yielding substantial amounts of the open-ring form, which is poorly absorbed.

Renal dysfunction may decrease topotecan plasma clearance. Creatinine clearance is significantly, but poorly, correlated with topotecan clearance. Hepatic impairment does not influence topotecan disposition.

Indices of systemic exposure (steady-state concentrations and AUC) are correlated with the extent of myelotoxicity. Sigmoidal functions adequately describe the relationships between systemic exposure and the percentage decrease in neutrophils.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Costin D, Potmesil M. Preclinical and clinical development of camptothecins. Adv Pharmacol 1994; 29B: 51–72

    Article  PubMed  CAS  Google Scholar 

  2. Wall ME, Wani MC, Cook CE, et al. Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumour inhibitor from Camptotheca acuminata. J Am Chem Soc 1966; 88: 3888–90

    CAS  Google Scholar 

  3. Horwitz SB, Chang C-K, Grollman AP. Studies on camptothecin.1. Effects on nucleic acid and protein synthesis. Mol Pharmacol 1971; 7: 632–44

    CAS  Google Scholar 

  4. Kessel D, Bosmann HB, Lohr K. Camptothecin effects on DNA synthesis on murine leukaemia cells. Biochim Biophys Acta 1972; 269: 210–6

    Article  PubMed  CAS  Google Scholar 

  5. Gottlieb JA, Guarino AM, Call JB, et al. Preliminary pharmacologic and clinical evaluation of camptothecin sodium. Cancer Chemother Rep 1970; 54: 461–70

    PubMed  CAS  Google Scholar 

  6. Moertel CG, Schutt AJ, Reitemeier RJ, et al. Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother Rep 1972; 56: 95–7

    PubMed  CAS  Google Scholar 

  7. Muggia FM, Creaven PJ, Hansen H, et al. Phase I clinical trial of weekly and daily treatment with camptothecin: correlation with preclinical studies. Cancer Chemother Rep 1972; 56: 515–21

    PubMed  CAS  Google Scholar 

  8. Hsiang Y-H, Hertzberg R, Hecht S, et al. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 1985; 260: 14873–5

    PubMed  CAS  Google Scholar 

  9. Hsiang Y-H, Liu LF. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 1988; 48: 1722–6

    PubMed  CAS  Google Scholar 

  10. Giovanella BC, Stehlin JS, Wall ME, et al. DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science 1989; 246: 1046–8

    Article  PubMed  CAS  Google Scholar 

  11. Husain I. Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: demonstration of tumor-type specificity and implications for cancer chemotherapy. Cancer Res 1994; 54: 539–46

    PubMed  CAS  Google Scholar 

  12. McLeod HL, Douglas F, Oates M, et al. Topoisomerase I and II activity in human breast, cervix, lung and colon cancer. Int J Cancer 1994; 59: 607–11

    Article  PubMed  CAS  Google Scholar 

  13. Jaxel C, Kohn KW, Wani MC, et al. Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase. I. Evidence of a specific receptor site and for a relation to antitumor activity. Cancer Res 1989; 49: 1465–9

    CAS  Google Scholar 

  14. Hsiang Y-H, Liu LF, Wall ME, et al. DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogs. Cancer Res 1989; 49: 4385–9

    PubMed  CAS  Google Scholar 

  15. Hertzberg RP, Caranfa MJ, Holden KG, et al. Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity. J Med Chem 1989; 32: 715–20

    Article  PubMed  CAS  Google Scholar 

  16. O'Dwyer PJ, Lacreta FP, Haas NB, et al. Clinical, pharmacokinetic and biological studies of topotecan. Cancer Chemother Pharmacol 1994; 34: 46S–52S

    Article  Google Scholar 

  17. Von Hoff DD, Burris HA III, Eckardt J, et al. Preclinical and phase I trials of topoisomerase I inhibitors. Cancer Chemother Pharmacol 1994; 34: 41S-45S

    Article  Google Scholar 

  18. Creemers GJ, Lund B, Verweij J. Topoisomerase I inhibitors: topotecan and irenotecan. Cancer Treat Rev 1994; 20: 73–96

    Article  PubMed  CAS  Google Scholar 

  19. Verweij J, ten Bokkel Huinink W, Lund B, et al. Clinical trials of topotecan in Europe. In: Potmesil M, Pinedo H, editors. Camptothecins: new anticancer agents. Boca Raton: CRC Press, 1995: 105–12

    Google Scholar 

  20. Underberg WJM, Goossen RMJ, Smith BR. Equilibrium kinetics of the new experimental anti-tumour compound SK&F 104864-A in aqueous solution. J Pharm Biomed Anal 1990; 8: 681–3

    Article  PubMed  CAS  Google Scholar 

  21. Fassberg J, Stella VJ. A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues. J Pharm Sci 1992; 81: 676–84

    Article  PubMed  CAS  Google Scholar 

  22. Rosing H, Doyle E, Davies BE, et al. High-performance liquid Chromatographie determination of the novel antitumour drug topotecan and topotecan as the total of the lactone plus carboxylate forms, in human plasma. J Chromotogr B Biomed Appl 1995; 668: 107–11

    Article  CAS  Google Scholar 

  23. Beijnen JH, Smith BR, Keijer WJ, et al. High-performance liquid Chromatographie analysis of the new antitumour drug SK&F 104864-A (NSC 609699) in plasma. J Pharm Biomed Anal 1990; 8: 789–94

    Article  PubMed  CAS  Google Scholar 

  24. Burke TG, Munshi CB, Mi Z. The important role of albumin in determining the relative human blood stabilities of the camptothecin anticancer drugs. J Pharm Sci 1995; 84: 518–9

    Article  PubMed  CAS  Google Scholar 

  25. Grochow LB, Rowinsky EK, Johnson R, et al. Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer. Drug Metab Dispos 1992; 20: 706–13

    PubMed  CAS  Google Scholar 

  26. Saltz L, Sirott M, Young C, et al. Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor. J Natl Cancer Inst 1993; 85: 1499–507

    Article  PubMed  CAS  Google Scholar 

  27. Burris III HA, Awada A, Kuhn JG, et al. Phase I and pharmaconetic studies of topotecan administered as a 72 or 120 h continuous infusion. Anticancer Drugs 1994; 5: 394–402

    Article  PubMed  Google Scholar 

  28. Van Warmerdam LJC, Creemers GJ, Rodenhuis S, et al. Pharmacokinetics and pharmacodynamics of topotecan administered at a daily times five schedule in phase II clinical trials using a limited sampling procedure. Cancer Chemother Pharmacol 1996; 38: 254–60

    Article  PubMed  Google Scholar 

  29. Van Warmerdam LJC, ten Bokkel Huinink WW, Rodenhuis S, et al. Phase I clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion [published eratum appears in J Clin Oncol 1996; 14: 689]. J Clin Oncol 1995; 13: 1768–76

    PubMed  Google Scholar 

  30. Tong W, Saltz L, Sirott M, et al. Rapid HPLC assay for topotecan [abstract]. Proc Am Assoc Cancer Res 1991; 32: 433

    Google Scholar 

  31. Loos WJ, Stoter G, Verweij J, et al. Sensitive high-performance liquid Chromatographie fluorescence assay for the quantitation of topotecan (SKF 104864-A) and its lactone ringopened product (hydroxy-acid) in human plasma and urine. J Chromotogr B Biomed Appl 1996; 678: 309–15

    Article  CAS  Google Scholar 

  32. Plaxe S, Christen R, O'Quigley J, et al. Phase I trial of intraperitoneal topotecan [abstract]. Proc Am Soc Clin Oncol 1993; 12: 140

    Google Scholar 

  33. Wall JG, Burris III HA, Von Hoff DD, et al. A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days. Anticancer Drugs 1992; 3: 337–45

    Article  PubMed  CAS  Google Scholar 

  34. Hasegawa K, Nishimura R, Fukuoka M, et al. Phase I and pharmacologic evaluation of topotecan on a 30 minute infusion [abstract]. Proc Am Assoc Cancer Res 1993; 34: 421

    Google Scholar 

  35. Verweij J, Lund B, Beijnen J, et al. Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor. Ann Oncol 1993; 4: 673–8

    PubMed  CAS  Google Scholar 

  36. Haas NB, LaCreta FP, Walczak J, et al. Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly. Cancer Res 1994; 54: 1220–6

    PubMed  CAS  Google Scholar 

  37. Blaney SM, Balis FM, Cole DE, et al. Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion. Cancer Res 1993; 53: 1032–6

    PubMed  CAS  Google Scholar 

  38. Reid JM, Burch PA, Benson LM, et al. Phase I clinical and pharmacological evaluation of topotecan administered by a 24 hour continuous infusion [abstract]. Proc Am Assoc Cancer Res 1992: 33: 259

    Google Scholar 

  39. Abbruzzese JL, Madden T, Schmidt S, et al. Phase I trial of topotecan administered by 24-hour infusion without and with G-CSF [abstract]. Proc Am Assoc Cancer Res 1993; 34: 329

    Google Scholar 

  40. Stewart CF, Baker SD, Heideman RL, et al. Clinical pharmacodynamics of continuous infusion topotecan in children: systemic exposure predicts hematologic toxicity. J Clin Oncol 1994; 12: 1946–54

    PubMed  CAS  Google Scholar 

  41. Rowinsky EK, Adjei A, Donehower RC, et al. Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia. J Clin Oncol 1994; 12: 2193–203

    PubMed  CAS  Google Scholar 

  42. Hochster H, Liebes L, Speyer J, et al. Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen. J Clin Oncol 1994; 12: 553–9

    PubMed  CAS  Google Scholar 

  43. Rowinsky EK, Grochow LB, Hendriks CB, et al. Phase I and pharmacologie study of topotecan: a novel topoisomerase I inhibitor. J Clin Oncol 1992; 10: 647–56

    PubMed  CAS  Google Scholar 

  44. Van Warmerdam LJC, Verweij J, Schellens JHM, et al. Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks. Cancer Chemother Pharmacol 1995; 35: 237–45

    Article  PubMed  Google Scholar 

  45. Herben VMM, ten Bokkel Huinink WW, Schot M, et al. Continuous infusion of low dose topotecan: a clinical pharmacologie phase II study in patients with small cell lung cancer [abstract]. Sixth Conference on DNA Topoisomerases in Therapy: 1995 Sep 6–8; Amsterdam, 77

  46. Creemers GJ, Gerrits CHJ, Planting AST, et al. Phase II study with topotecan administered as a 21 -day continuous infusion to patients with colorectal cancer [abstract]. Eur J Cancer 1995; 31A: S146

    Article  Google Scholar 

  47. Pratt CB, Stewart C, Santana VM, et al. Phase I study of topotecan for pediatric patients with malignant solid tumors. J Clin Oncol 1994; 12: 539–43

    PubMed  CAS  Google Scholar 

  48. Topotecan (SK&F 104864-A): investigator brochure. Philadelphia: Smith, Kline and French Laboratories, 1990

  49. Cole DE, Blaney SM, Balis FM. Topotecan in physiologic fluids: depot of active drug in red blood cells. Proc Am Assoc Cancer Res 1995; 36: 363

    Google Scholar 

  50. Munshi CB, Mi Z, Burke TG. The biophysics underlying the favorable stability of the topotecan anticancer drug in human blood [abstract]. Proc Am Assoc Cancer Res 1995; 36: 444

    Google Scholar 

  51. Burke T, Mi Z, Roy D, et al. The pivotal role of albumin in determining the relative blood stabilities of camptothecin analogs presently in clinical trials [abstract]. Proc Am Soc Clin Oncol 1995; 14: 463

    Google Scholar 

  52. Baker SD, Heideman RI, Kuttesch JF, et al. CNS penetration of topotecan following continuous infusion in children with cancer. Clin Pharmacol Ther 1994; 55: 189

    Google Scholar 

  53. Van Warmerdam LJC, Rosing H, ten Bokkel Huinink WW, et al. Do topotecan concentrations in saliva reflect plasma concentrations? J Oncol Pharm Pract 1995; 1: 41–5

    Article  Google Scholar 

  54. Scott DO, Bindra DS, Sutton SC, et al. Urinary and biliary disposition of the lactone and carboxylate forms of 20(S)-camptothecin in rats. Drug Metab Dispos 1994; 22: 438–42

    PubMed  CAS  Google Scholar 

  55. Recondo G, Abbruzzese J, Newman B, et al. A phase I trial of topotecan administered by a 24-hr infusion [abstract]. Proc Am Assoc Cancer Res 1991; 32: 206

    Google Scholar 

  56. Borkowski JM, Duerr M, Donehower RC, et al. Relation between age and clearance rate of nine investigational anticancer drugs from phase I pharmacokinetic data. Cancer Chemother Pharmacol 1994; 33: 493–6

    Article  PubMed  CAS  Google Scholar 

  57. Van Warmerdam LJC, Verweij J, Rosing H, et al. Limited sampling models for topotecan pharmacokinetics. Ann Oncol 1994; 5: 259–64

    PubMed  Google Scholar 

  58. Leonard TB, Fish CJ, Smith B, et al. Toxicity and toxicokinetics of topotecan in dogs following intravenous and oral administration [abstract]. Proc Am Assoc Cancer Res 1994; 35: 461

    Google Scholar 

  59. Davies BE, Minthorn EA, Dennis M, et al. The pharmacokinetics of topotecan and its carboxylate form following separate intravenous administration to the dog [abstract]. Eur J Cancer 1995; 31A: S192

    Google Scholar 

  60. Creemers GJ, Schellens JHM, Beijnen JH, et al. Bioavailability of oral topotecan, a new topoisomerase I inhibitor [abstract]. Proc Am Soc Clin Oncol 1994; 13: 132

    Google Scholar 

  61. Eckardt J, Burris H, Rizzo J, et al. A phase I safety and bioavailability study of oral topotecan [abstract]. Eur J Cancer 1995; 31A: S193

    Article  Google Scholar 

  62. Schellens JHM, Eckardt JR, Verweij J, et al. Pharmacokinetics, clinical pharmacodynamics and safety of chronic oral topotecan in a phase I study [abstract]. Eur J Cancer 1995; 31A: S28

    Google Scholar 

  63. Cheng H, Jusko WJ. Pharmacokinetics of reversible metabolic systems. Biopharm Drug Dispos 1993; 14: 721–66

    Article  PubMed  CAS  Google Scholar 

  64. Grochow LB, Slichenmyer W, Rowinsky E, et al. Phase I clinical and pharmacologie study of topotecan in patients with hepatic or renal dysfunction [abstract]. Eighth NCI-EORTC Symposium on New Drugs in Cancer Chemotherapy; 1994 Mar 15–18; Amsterdam, 19

  65. Slichenmyer W, Chen T-L, Donehower R, et al. Clinical pharmacology of topotecan in cancer patients with renal or hepatic dysfunction [abstract]. Proc Am Soc Clin Oncol 1994; 13: 142

    Google Scholar 

  66. Zamboni WC, Heideman RL, Meyer WH, et al. Pharmacokinetics (PK) of topotecan (TPT) in pediatric patients with normal and altered renal function [abstract]. Proc Am Soc Clin Oncol 1996; 15: 180

    Google Scholar 

  67. Burris III HA, Hanauske AR, Johnson RK, et al. Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units. J Natl Cancer Inst 1992; 84: 1816–20

    Article  PubMed  CAS  Google Scholar 

  68. Houghton PJ, Cheshire PJ, Hallman II JD, et al. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol 1995; 36: 393–403

    Article  PubMed  CAS  Google Scholar 

  69. Hochster H, Liebes L, Sorich J, et al. Increasing cleavable complex formation in peripheral blood lymphocytes with increasing topotecan infusion duration: a rationale for prolonged administration of camptothecins [abstract]. Sixth Conference on DNA Topoisomerases in Therapy. 1995 Sep 6–8; Amsterdam, 88

  70. Hutson PR, Kim K, Johnson D, et al. Pharmacodynamic evaluation of the response of extensive stage small cell lung cancer to topotecan [abstract]. Proc Am Soc Clin Oncol 1995; 14: 460

    Google Scholar 

  71. Stewart CF, Baker SD, Furman WL, et al. Targeting plasma concentrations of topotecan during a 120-hr continuous infusion in children with relapsed acute leukemia [abstract]. Clin Pharmacol Ther 1995; 57: 176

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacy and Pharmacology, Slotervaart Hospital/Netherlands Cancer Institute, Louwesweg 6, 1066 EC, Amsterdam, The Netherlands

    Virginie M. M. Herben & Jos H. Beijnen

  2. Department of Medical Oncology, Netherlands Cancer Institute and Slotervaart Hospital, Amsterdam, The Netherlands

    Virginie M. M. Herben, Wim W. ten Bokkel Huinink & Jos H. Beijnen

Authors
  1. Virginie M. M. Herben
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wim W. ten Bokkel Huinink
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jos H. Beijnen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Virginie M. M. Herben.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Herben, V.M.M., ten Bokkel Huinink, W.W. & Beijnen, J.H. Clinical Pharmacokinetics of Topotecan. Clin-Pharmacokinet 31, 85–102 (1996). https://doi.org/10.2165/00003088-199631020-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-199631020-00001

Keywords

Search

Navigation